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ABSTRACT: As part of a program to develop a small molecule inhibitor of LIMK, a series of aminothiazole inhibitors were discov-
ered by high throughput screening. Scaffold hopping and subsequent SAR directed development led to a series of low nanomolar 
inhibitors of LIMK1 and LIMK2 that also inhibited the direct biomarker p-cofilin in cells and inhibited the invasion of MDA MB-
231-luc cells in a matrigel inverse invasion assay. 
Tumour cell invasion and metastasis are the primary causes of 
mortality in cancer patients. During progression of tumour cells 
to a metastatic phenotype, they undergo a series of changes that 
begin with loss of contact inhibition and increased motility, al-
lowing them to migrate from the primary tumour site, invade 
distant organs and induce neovascularization resulting in me-
tastasis.1 Despite numerous developments, cancer cell invasion 
and metastasis is still a poorly studied process. Most strategies 
to treat cancer do not rely on inhibiting invasion and metastasis 
as the primary phenotype due to the requirement for lengthy and 
complicated clinical trials. However a detailed understanding of 
the drivers of cancer cell invasion and migration is essential to 
develop new treatments for cancer patients.  
The LIM kinases (LIMK1 and LIMK2; collectively LIMK) are 
TKL kinases that act downstream of Rho GTPases. LIM kinases 
phosphorylate and inactivate the filamentous-actin severing 
protein cofilin. Cycles of cofilin inactivation and activation en-
able dynamic actin rearrangements that are required for cell mo-
tility (Figure 1). Once phosphorylated at Ser3 by the LIM ki-
nases cofilin can no longer bind to actin leading to the accumu-
lation of actin polymers. LIM kinases are therefore centrally po-
sitioned regulators of actin cytoskeletal dynamics and also play 
important roles in microtubule organization.2,3  
LIMK1 has been reported to play a key regulatory role in tu-
mour cell invasion and the level of LIMK1 is increased in inva-
sive breast,4 prostate,5 and pancreatic6 cancer cell lines in com-
parison with less invasive cells. Overexpression of LIMK1 in 
MCF-7 and in MDA MB-231 human breast cancer cell lines 
increased their motility, while inhibition of LIMK1 activity in 
MDA MB-231 cells by expression of a dominant negative 
LIMK1 resulted in decreased motility and formation of osteo-
lytic bone lesions in an animal model of tumour invasion.7 As 
such, the LIM kinases have been proposed to be attractive drug 
targets to block tumour cell invasion and metastasis. 
 
Figure 1 LIMK’s are key regulators of the actin cytoskeleton, 
through their modulation of cofilin function.  
A number of groups have previously reported inhibitors of the 
LIM kinases9-13 as treatments for cancer and for their ability to 
lower intraocular pressure for glaucoma. Herein we describe the 
discovery and development of a series of LIMK inhibitors that 
demonstrate inhibition of p-cofilin and inhibit invasion of can-
cer cells in a 3D inverse invasion assay. 
We used a commercially available kinase Glo® kit measuring 
ATP depletion using full length LIMK and cofilin to screen 
60,000 compounds.14 From this we identified two lead series, a 
series of pyrimidines that our partners CTx developed15,16 and a 
 series of aminothiazoles exemplified by 1 LIMK1 IC50=4 µM 
(Figure 2) as modestly potent inhibitors of LIMK1. Although 
these compounds could be improved in terms of their isolated 
enzyme potency, no evidence of activity in the cellular assay 
was observed. They also contained numerous undesirable func-
tionalities such as an alkene, a ketone and a potentially unstable 
methylene dioxy group. In removing the amino functionality, 
we reasoned that we could improve the cellular potency by re-
ducing the H bond count. We also removed the undesirable ke-
tone functionality, replacing it with a variety of groups. This led 
to pyridine 2 a compound that was similarly potent to the orig-
inal hit 1. Bristol Myers Squibb reported that substituted pyra-
zoles with an aryl di-ortho chloro group were potent LIMK in-
hibitors.13 Similarly we found that pyridines substituted with 
aryl rings adjacent to the thiazole ring provided substantial im-
provements in potency as in 3a which had a LIMK1 potency of 
15 nM. Even more importantly compound 3a was active in the 
p-cofilin cellular assay with an IC50=3 µM.   
Figure 2 Evolution from original HTS lead 
In order to better understand the binding mode, we created a 
homology model of the kinase domain of hLIMK1 based on c-
Src (PDB code 1Y57.pdb) as a template. hLIMK shares 33.5% 
sequence identity and 50.6% sequence similarity with the c-Src 
template.  Whilst there are some sequence inserts in the activa-
tion loop region (LIMK1 compared with c-Src) the rest of the 
sequences align well with no major inserts or deletions.  
The improvements in potency were explained by docking 3a 
into the homology model (Figure 3). The amino thiadiazole in 
1, 2 and 3a can form the key donor-acceptor interaction to the 
Ile428, Tyr 427 hinge residues. The pyridyl nitrogen present in 
2 and 3a is well placed to interact with the salt bridge Lys380 
residue. This agreed well with the SAR because the other pyri-
dine isomers 4, 5 and 6 were much less potent than 3a (Figure 
4). The chlorine atom was postulated to be making a halogen 
bond interaction to the Val 378 residue. 
 
Figure 3 Compound 3a docked into a LIMK1 homology model 
based on c-Src (PDB code 1Y57.pdb) with surfaces coloured by 
lipophilicity, with purple indicating hydrophilic surfaces, green 
indicating lipophilic surfaces and neutral areas of the surface in 
white. Dotted lines indicate the key bonding interactions be-
tween the ligand and protein.  
 
Figure 4 Pyridine isomer SAR 
To understand the SAR and key binding interactions we set out 
to synthesize analogues of the cell active lead 3a. A variety of 
synthetic strategies were employed to allow late stage modifi-
cations of either the aryl ring (Scheme 1) or the amine side chain 
attached to the aminothiazole (Schemes 2 and 3).  
Starting from the commercially available 3-bromopyridine-4-
carbaldehyde 7 and reducing to the alcohol 8 followed by chlo-
rination with thionyl chloride to the benzyl chloride 9 proceeded 
smoothly. The thiazole ring could then be constructed by heat-
ing in acetonitrile with triethylamine and the appropriate ami-
dines 10a-10c to provide the thiazoles 11 a-c. Protection of 11a 
with a Boc group allowed the introduction of a range of aryl 
groups via a Suzuki coupling to furnish after deprotection with 
TFA the final compounds 3a-3h. Compound 3i was prepared 
by an alternative route from 11b by di Boc protection to give 13 
followed by Suzuki coupling to afford 14a, 
Scheme 1 Synthetic access to aryl substituted pyridine ana-
logues 
Reagents and conditions: (i) NaBH4, MeOH, rt (ii) SOCl2, 
DCM, DMF, reflux (iii) MeCN, 10a, 10b or 10c, Et3N, reflux 
(iv) Boc2O, DMAP, DCM, rt (v) (PPh3)2PdCl2, R
2ArB(OH)2, 
K2CO3, 1,4-dioxane, water, 150 °C (vi) TFA (vii) 3 equivs 
Boc2O, DMAP, THF (viii) (PPh3)2PdCl2, 2-chlorophenyl-
boronic acid, K2CO3, 1,4-dioxane, water, 150 °C then TFA (ix) 
NaNO2, HCl (x) NHMePr, MeOH, 150 °C 
 
 
 
 
Ile428 
Tyr427 
Val378 
Lys380 
Thr425 
 Table 1 Initial aryl ring SAR investigations 
 
*measured in ZR75-1 cells using a Cellomics array scan instru-
ment. ND=not determined. 
that could then be converted to the chloride 15 by diazotization 
in hydrochloric acid. Displacement with N-propylmethylamine 
gave the final target 3i. 
Initial SAR modifications focused mainly on the aryl ring (Ta-
ble 1) and demonstrated that the presence of an ortho substitu-
ent was required to provide activity, in particular where the 
group was ortho chloro as shown in entry 3a. The ortho chloro 
group could be replaced with methyl or trifluoro methyl alt-
hough larger groups such as iso-propyl resulted in large losses 
in LIMK1 potency. Removal of the propyl side chain as in entry 
14 or methylation of the NH as in entry 3i resulted in large 
losses in potency with the latter result being consistent with the 
proposed binding mode where the NH forms a key donor inter-
action to the hinge region of the kinase (Figure 3). 
The amine side chain could be modified (Scheme 2) by di Boc 
protection of 11b to give 13 followed by a Suzuki coupling gave 
the Boc protected and the unprotected compounds 14a and 16 
respectively. The mono Boc protected aminothiazole 14a could 
be derivatised using a Mitsunobu coupling providing a conven-
ient method to deliver benzylamines 3l and 3m. Alternatively 
11b could be mono Boc protected to give 17, the amine side 
chain could be introduced via a Mitsunobu coupling to give 18a 
and 18b. Suzuki couplings provided access to the targets 3j and 
3k. Using an analogous strategy that was employed in (Scheme 
1) N-aryl analogues could be introduced by Boc protection of 
11c to afford 19 and subsequent Suzuki coupling to yield 3n. 
 
 
 
 
Scheme 2 Synthetic strategy to access amine side chain an-
alogues 
Reagents and conditions: (i) 3 equivs Boc2O, DMAP, THF (ii) 
(PPh3)2PdCl2, 2-chlorophenylboronic acid, K2CO3, 1,4-diox-
ane, water, 150 °C (iii) R1OH, DIAD, PPh3, THF (iv) TFA, 
DCM (v) Boc2O, DMAP, DCM (vi) Boc2O, DMAP, DCM 
To allow further diversification of the aminothiazole side chain 
at the last step the aryl rings could be introduced on the alcohol 
intermediates 20a and 20b (Scheme 3), followed by chlorina-
tion to provide 21a and 21b, thiazole formation with 10b or 10d 
provided final compound 3o and intermediates 14b-c. This then 
allowed for a series of amides to be prepared 22a-d.  
The N-aryl analogue 3n in particular was very potent providing 
a compound that was sub micromolar in the p-cofilin cellular 
assay. Smaller alkyl groups such as ethyl 3j were less potent 
compared to iso-butyl 3k and benzylamines 3l and 3m. Amides 
22a-22d were also well tolerated particularly 22b which was 
0.8 µM in the p-cofilin cellular assay. 
Scheme 3 Synthetic strategy to access amide side chain an-
alogues 
Reagents and conditions: (i) (PPh3)2PdCl2, R
2ArB(OH)2, 
K2CO3, 1,4-dioxane, water, 150 °C (ii) SOCl2, DCM, DMF, re-
flux (iii) MeCN, 10b or 10d, Et3N, reflux (iv) R
3COCl, Et3N, 
DCM, rt 
 
Entry R1 R2 LIMK1 
IC50 µM 
Cell p-cofilin* 
IC50 µM 
3a -NHPr 0-Cl 0.015 3.8 
3b -NHPr m-Cl 0.50 ND 
3c -NHPr p-Cl 0.62 ND 
3d -NHPr H 0.85 ND 
3e -NHPr o-Me 0.082 11.5 
3f -NHPr o-i-Pr 3.3 ND 
3g -NHPr o-CF3 0.037 2.2 
3h -NHPr 0-CF3, 
p-OMe 
0.013 2.5 
14a -NH2 o-Cl 0.27 >30 
3i -NMePr o-Cl 3.1 ND 
 Table 2. SAR of amine side chain modifications 
 
Entry R1 R2 LIMK1 
IC50 
µM 
Cell p-co-
filin* IC50 
µM 
3j -NHEt o-Cl 0.12 14 
3k -NH-i-Bu o-Cl 0.005 1.5 
3l -NHCHMe(S)Ph o-Cl 0.04 9.2 
3m -NHCHMe(R)Ph o-Cl 0.004 2.1 
3n -NHPh o-Cl 0.003 0.6 
3o -NH-4-PhOH o-Cl, p-
Me 
0.0003 6.6 
22a -NHCOMe o-Cl 0.02 1.4 
22b -NHCO-i-Pr o-Cl 0.003 0.8 
22c -NHCO-i-Pr o-Cl, p-
Me 
0.001 ND 
22d -NHCO-i-Pr o-CF3, 
p-OMe 
0.008 2.0 
*measured in ZR75-1 cells using a Cellomics array scan instru-
ment. ND=not determined. 
The ADME properties of the compounds required optimisation, 
in particular the alkyl substituted analogues were liable to high 
metabolic turnover in vitro. However the propyl group could be 
replaced with N-aryl analogues and amide groups. The amide 
analogue 22d in particular had lower in vitro microsomal turn-
over (Table 3).  
Table 3. ADME properties and isoform selectivity of se-
lected analogues 
Entry 22c 22d 3o 
LIMK1 IC50/nM 1 8 0.3 
LIMK2 IC50/nM 3 48 1 
cLogP 4.2 4.3 4.8 
Microsomes (m/h) 
mL/min/g liver 
19.4/8.3 5.2/3.7 4.5/0.9 
PPB (h)/% 100 100 100 
In order to understand the functional effects of the compounds, 
we employed a 3D inverse invasion assay17 to measure the in-
hibition of invasion of cells into a matrigel matrix. In order to 
purely understand the metastatic phenotype it was necessary to 
select non-toxic compounds, so cell viability at 10 µM was 
measured. We used an MTT cytotoxicity assay to select four 
compounds for further investigation based on their lack of cy-
totoxic effects (Table 4). To measure the invasive phenotype, 
MDA MB-231-luc cells were plated on the underside of a 
transwell filter plate. The ability of cells to invade was meas-
ured by confocal microscopy of sections through a matrigel 
plug. The percentage inhibition of invasion was measured as a 
function of the proportion of cells that invaded more than 60 
µm into the matrigel plug compared to cells that invaded less 
than 60 µm, relative to the control. Compounds 3k, 22c, 22d 
and 3o all inhibited the invasion of the cells through matrigel at 
a concentration of 3 µM, whilst not significantly affecting cell 
viability even at the higher compound concentration of 10 µM. 
Compound 3o was found to be the most effective at inhibiting 
invasion. However the more selective compound 22d also sig-
nificantly inhibited the invasion of the cells by 52%. In addition, 
two other compounds 3k and 22c also inhibited invasion with-
out having a marked effect on cell viability. 
Table 4. Functional effects of selected LIMK inhibitors in 
an inverse invasion assay 
Entry MTT % viable 
cells@ 10 µM 
 inhibitor 
% inhibition of in-
vasion@ 3 µM in 
MDA MB-231-luc  
3k 88% 34 (n=5) 
22c 131% 48 (n=2) 
22d 106% 52 (n=3) 
3o 70% 96 (n=3) 
To measure selectivity against the LIMK2 isoform we devel-
oped an assay using a lanthabind format. The compounds were 
similarly potent Vs LIMK2 as LIMK1 (Table 3).  The lead com-
pounds were also profiled for their selectivity against a broader 
panel of 442 kinases using KINOMEscan® at Millipore (now 
DisoveRx). The selectivity of 22d, 3o and 22c is represented in 
the kinome phylogenetic trees from screening at 10 µM inhibi-
tor concentration (Figure 5). Selectivity scores were calculated 
as the number of non mutant kinases with % activity relative to 
control <35/number of non mutant kinases tested. Compounds 
22d and 22c were the particularly selective with selectivity 
S(35) scores of 0.083 and 0.132 respectively. 
 
Figure 5 Kinase selectivity Vs 442 kinases for compounds 22d, 
3o and 22c 
In summary we have developed a series of novel LIMK inhibi-
tors that are effective in inhibiting cellular invasion through a 
3D matrix. An additional publication by Olson et al.18 will de-
tail further biological data using compounds 22d and 3o (also 
known as CRT0105446 and CRT0105950 respectively) to in-
vestigate the effects of LIMK inhibition on microtubule organ-
isation. The lead compounds are available externally for further 
profiling and investigation to determine their pharmacological 
applicability in conditions where LIMK plays a role. 
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ABBREVIATIONS 
TFA: Trifluoroacetic acid, DCM: Dichloromethane, DMF: N, N-
Dimethyl formamide, DMAP: 4-N,N-Dimethyl amino pyridine, 
THF: Tetrahydrofuran, DIAD: Di-iso-propyl azodicarboxylate: 
MeCN: Acetonitrile, Boc: tert-Butyloxy carbonyl, PPB: Plasma 
protein binding, MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide, RPMI: Roswell park memorial institute: FCS: 
Fetal calf serum, EGF: Epithelial growth factor, TKL: Tyrosine ki-
nase like, GTP: Guanosine-5'-triphosphate, ATP: Adenosine tri-
phosphate; HTS: High throughput screen;  SAR: Structure activity 
relationship; PDB: Protein data bank; MOE: Molecular operating 
environment; ND: Not determined; m: mouse; h: human. 
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